-transparent.png){kind=logo}
BACKGROUND A polyclonal antihuman c-erbB-2 oncoprotein antibody recognized c-erbB-2 oncoprotein in routinely formaldehyde-fixed, paraffin-embedded specimens. METHODS Specimens taken from 192 patients with Stage III squamous cell carcinoma of the cervix treated with radiation therapy alone were investigated for c-erbB-2 oncoprotein expression using an immunohistochemical method. RESULTS Cancer cells that were positive for c-erbB-2 oncoprotein showed a surface membrane staining pattern. Of the 192 patients, 143 were negative for c-erbB-2 oncoprotein, 12 were weakly positive or ambiguous, 31 were positive, and 6 were strongly positive. The 5-year survival rate of the 155 patients who tested c-erbB-2 negative or weakly positive was significantly better than that of the 37 patients whose results were positive or strongly positive (61% versus 41%, P = 0.022). CONCLUSIONS c-erbB-2 Oncoprotein expression in cancer cells may imply a poor prognosis for patients with Stage III squamous cell carcinoma of the cervix treated with radiation therapy alone.
K Oka, and
T Nakano, and
T Arai
May 2001,
International journal of cancer,
K Oka, and
T Nakano, and
T Arai
December 2003,
International journal of radiation oncology, biology, physics,
K Oka, and
T Nakano, and
T Arai
June 1991,
Cancer,
K Oka, and
T Nakano, and
T Arai
January 2018,
International journal of clinical and experimental pathology,
K Oka, and
T Nakano, and
T Arai
February 2006,
International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics,
K Oka, and
T Nakano, and
T Arai
June 2014,
BMC cancer,
K Oka, and
T Nakano, and
T Arai
December 1989,
Oncogene,
K Oka, and
T Nakano, and
T Arai
March 2018,
Oncology letters,
K Oka, and
T Nakano, and
T Arai
January 2003,
Revista medico-chirurgicala a Societatii de Medici si Naturalisti din Iasi,
K Oka, and
T Nakano, and
T Arai
October 1997,
American journal of clinical pathology,
